UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Journal of medicinal chemistry, 2022-01, Vol.65 (1), p.58-83

2022

Volltextzugriff (PDF)

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects

Journal of medicinal chemistry, 2019-03, Vol.62 (6), p.2905-2915

2019

Volltextzugriff (PDF)

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4

Journal of medicinal chemistry, 2022-03, Vol.65 (6), p.5113-5133

2022

Volltextzugriff (PDF)

The feline skin microbiota: The bacteria inhabiting the skin of healthy and allergic cats

PloS one, 2017-06, Vol.12 (6), p.e0178555-e0178555

2017

Volltextzugriff (PDF)

The skin microbiome in healthy and allergic dogs

PloS one, 2014-01, Vol.9 (1), p.e83197-e83197

2014

Volltextzugriff (PDF)

Exploration of anomalous perceptual experiences in migraine between attacks using the Cardiff Anomalous Perceptions Scale

Consciousness and cognition, 2020-07, Vol.82, p.102945-17, Article 102945

2020

Volltextzugriff (PDF)

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

ChemMedChem, 2019-02, Vol.14 (4), p.494-500

2019

Volltextzugriff (PDF)

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Clinical cancer research, 2021-03, Vol.27 (5), p.1463-1475

2021

Volltextzugriff (PDF)

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

Journal of structural biology, 2015-12, Vol.192 (3), p.539-544

2015

Volltextzugriff (PDF)

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations

Journal of medicinal chemistry, 2023-09, Vol.66 (17), p.11656-11671

2023

Volltextzugriff (PDF)

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

Biochemical journal, 2015-10, Vol.471 (2), p.131-153

2015

Volltextzugriff (PDF)

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

Cells (Basel, Switzerland), 2021-04, Vol.10 (5), p.1006

2021

Volltextzugriff (PDF)

Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery

Molecular diagnosis & therapy, 2024-03, Vol.28 (2), p.141-151

2024

Volltextzugriff (PDF)

What is living on your dog's skin? Characterization of the canine cutaneous mycobiota and fungal dysbiosis in canine allergic dermatitis

FEMS microbiology ecology, 2015-12, Vol.91 (12), p.1

2015

Volltextzugriff (PDF)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2372-2383

2021

Volltextzugriff (PDF)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Clinical and translational radiation oncology, 2019-02, Vol.15, p.62-69

2019

Volltextzugriff (PDF)

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.740-751

2012

Volltextzugriff (PDF)

Design, Synthesis, and Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors

Journal of medicinal chemistry, 2022-11, Vol.65 (21), p.14809-14831

2022

Volltextzugriff (PDF)

Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells

Journal of medicinal chemistry, 2022-10, Vol.65 (20), p.14032-14048

2022

Volltextzugriff (PDF)

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer

European journal of medicinal chemistry, 2018-03, Vol.147, p.238-252

2018

Volltextzugriff (PDF)

Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy

Biochemistry (Easton), 2019-09, Vol.58 (35), p.3700-3710

2019

Volltextzugriff (PDF)

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Molecules (Basel, Switzerland), 2020-10, Vol.25 (21), p.4888

2020

Volltextzugriff (PDF)

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623

International journal of molecular sciences, 2024-06, Vol.25 (12), p.6593

2024

Volltextzugriff (PDF)

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol

Bioorganic & medicinal chemistry letters, 2020-06, Vol.30 (11), p.127135-127135, Article 127135

2020

Volltextzugriff (PDF)

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

Cancer gene therapy, 2022-07, Vol.29 (7), p.1021-1032

2022

Volltextzugriff (PDF)

1 – 25 von 899

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(765)
Mit Volltextzugriff
(787)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(899)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4

The feline skin microbiota: The bacteria inhabiting the skin of healthy and allergic cats

The skin microbiome in healthy and allergic dogs

Exploration of anomalous perceptual experiences in migraine between attacks using the Cardiff Anomalous Perceptions Scale

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery

What is living on your dog's skin? Characterization of the canine cutaneous mycobiota and fungal dysbiosis in canine allergic dermatitis

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302

Design, Synthesis, and Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors

Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer

Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623

Alanine scan-guided synthesis and biological evaluation of analogues of culicinin D, a potent anticancer peptaibol

Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

Suchergebnisse filtern